Monday, 25 Sep 2017

You are here

FDA Approves Renflexis as Second Infliximab Biosimilar

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

This will be the fifth biosimilar to be FDA approved and the fourth TNF inhibitor.  In 2016, the FDA approved biosimilar versions of etanercept (Erelzi), adalimumab (Amjevita) and infliximab (Infectra or infliximab-dyyb).   This will be the second version of infliximab to hit the market and under the new naming system will have the generic name infliximab-abda.

Renflexis will carry the same indications of the originator (Remicade) including active, moderate-severe, rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

The drug is approved with the same dosing, boxed warnings (serious infections, TB, lymphoma, hepatosplenic T cell lymphoma) and warnings currently found with Remicade and Inflectra. Thus before starting Renflexis, patient must be screened for tuberculosis.

The company had filed for the U.S. FDA approval in March last year. Submitted supplemental data in December 2016 and was granted licensing privileges on 4/21/17. 

The drug is currently approved and in use in Korea under the brand name of Renflexis. It also approved throughout Europe, Norway, Iceland and Australia since 2016, where it is called Flixabi. 

Renflexis will be marketed and distributed in the United States by Merck & Co Inc.

Remicade accounted for about 9.7 percent of Johnson & Johnson's total revenues for fiscal 2016, and biosimilar competition is expected to reduce U.S. sales.

The package insert for Renflexis can be found here.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.  

Uveitis Events Reduced with Select TNF Inhibitors

Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.

No Increase in Malformations with Etanercept Use During Pregnancy

While there are several reports detailing uncontrolled, observational results of biologic use during pregnancy, most are hampered by low numbers, incomplete data and too small a sample to make reliable judgements regarding the teratogenicity.  A company sponsored claims data analysis has shown that etanercept exposure during pregnancy was not associated with an increase in major congenital malformations (MCMs).